Cytokinetics Stock Price, News & Analysis (NASDAQ:CYTK)

$7.80 +0.15 (+1.96 %)
(As of 02/22/2018 04:00 PM ET)
Previous Close$7.80
Today's Range$7.60 - $8.10
52-Week Range$7.00 - $17.20
Volume359,318 shs
Average Volume373,725 shs
Market Capitalization$417.61 million
P/E Ratio-3.04
Dividend YieldN/A
Beta1.03

About Cytokinetics (NASDAQ:CYTK)

Cytokinetics logoCytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.

Receive CYTK News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CYTK
CUSIPN/A
Phone650-624-3000

Debt

Debt-to-Equity Ratio0.29%
Current Ratio8.46%
Quick Ratio7.60%

Price-To-Earnings

Trailing P/E Ratio-3.03500764588465
Forward P/E Ratio-4.04
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.37 million
Price / Sales31.43
Cash Flow$0.43 per share
Price / Cash18.31
Book Value$2.04 per share
Price / Book3.82

Profitability

Trailing EPS($2.57)
Net Income$-127,790,000.00
Net Margins-172.27%
Return on Equity-96.95%
Return on Assets-41.65%

Miscellaneous

Employees127
Outstanding Shares53,880,000

Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

How were Cytokinetics' earnings last quarter?

Cytokinetics, Inc. (NASDAQ:CYTK) announced its earnings results on Thursday, February, 15th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.71) by $0.04. The biopharmaceutical company earned ($0.02) million during the quarter, compared to the consensus estimate of $4.83 million. Cytokinetics had a negative return on equity of 96.95% and a negative net margin of 172.27%. View Cytokinetics' Earnings History.

When will Cytokinetics make its next earnings announcement?

Cytokinetics is scheduled to release their next quarterly earnings announcement on Wednesday, April, 25th 2018. View Earnings Estimates for Cytokinetics.

Where is Cytokinetics' stock going? Where will Cytokinetics' stock price be in 2018?

9 analysts have issued 12-month price targets for Cytokinetics' shares. Their forecasts range from $10.00 to $25.00. On average, they expect Cytokinetics' share price to reach $16.78 in the next year. View Analyst Ratings for Cytokinetics.

What are Wall Street analysts saying about Cytokinetics stock?

Here are some recent quotes from research analysts about Cytokinetics stock:

  • 1. Cantor Fitzgerald analysts commented, "Robert Califf, M.D. has joined CYTK’s Board of Directors (BoD), adding his expertise in cardiovascular and regulatory domains, we believe." (2/12/2018)
  • 2. According to Zacks Investment Research, "Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. " (8/17/2017)
  • 3. Cowen Inc analysts commented, "CYTK reported a Q2 loss of $29.1MM and ended the quarter with $332MM in cash." (8/4/2017)
  • 4. Rodman & Renshaw analysts commented, "Our price target is based on our clinical net present value (NPV) model, which is currently driven by omecamtiv mecarbil ($19.77/share) and modest contributions from tirasemtiv ($4.26/share) and CK-107 ($1.05/share). We believe this method is appropriate in capturing the value of the clinical stage pipeline by allowing us to flex multiple assumptions, including chance of success, peak sales estimates, and year of commercial launch. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (3/23/2017)

Who are some of Cytokinetics' key competitors?

Who are Cytokinetics' key executives?

Cytokinetics' management team includes the folowing people:

  • Leonard Patrick Gage Ph.D., Independent Chairman of the Board (Age 74)
  • Robert I. Blum, President, Chief Executive Officer, Director (Age 53)
  • Ching Jaw, Chief Financial Officer, Senior Vice President (Age 54)
  • Sharon A. Barbari, Executive Vice President - Finance (Age 62)
  • Fady I. Malik M.D. Ph.D., Executive Vice President - Research and Development (Age 52)
  • Peter S. Roddy, Senior Vice President, Chief Accounting Officer (Age 57)
  • David W. Cragg, Senior Vice President - Human Resources (Age 61)
  • Bonnie A. Charpentier Ph.D., Senior Vice President - Regulatory Affairs and Compliance (Age 65)
  • Bradley Paul Morgan Ph.D., Senior Vice President - Research and Non-Clinical Development (Age 56)
  • Elisabeth Schnieders Ph.D., Senior Vice President - Business Development (Age 50)

Who owns Cytokinetics stock?

Cytokinetics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (13.44%), BVF Inc. IL (10.62%), BIOTECHNOLOGY VALUE FUND L P (10.10%), Wasatch Advisors Inc. (3.12%), Pinnacle Associates Ltd. (1.63%) and Bank of New York Mellon Corp (1.00%). Company insiders that own Cytokinetics stock include Bradley Paul Morgan, Caryn Gordon Mcdowell, Fady Ibraham Malik, Robert I Blum and Santo J Costa. View Institutional Ownership Trends for Cytokinetics.

Who sold Cytokinetics stock? Who is selling Cytokinetics stock?

Cytokinetics' stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Pinnacle Associates Ltd., Sphera Funds Management LTD., Schwab Charles Investment Management Inc., TIAA CREF Investment Management LLC, Metropolitan Life Insurance Co. NY and Bank of New York Mellon Corp. Company insiders that have sold Cytokinetics company stock in the last year include Bradley Paul Morgan, Caryn Gordon Mcdowell, Fady Ibraham Malik, Robert I Blum and Santo J Costa. View Insider Buying and Selling for Cytokinetics.

Who bought Cytokinetics stock? Who is buying Cytokinetics stock?

Cytokinetics' stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, Wasatch Advisors Inc., BlackRock Inc., Tekla Capital Management LLC, Goldman Sachs Group Inc., Deutsche Bank AG, Two Sigma Investments LP and Arizona State Retirement System. View Insider Buying and Selling for Cytokinetics.

How do I buy Cytokinetics stock?

Shares of Cytokinetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cytokinetics' stock price today?

One share of Cytokinetics stock can currently be purchased for approximately $7.80.

How big of a company is Cytokinetics?

Cytokinetics has a market capitalization of $417.61 million and generates $13.37 million in revenue each year. The biopharmaceutical company earns $-127,790,000.00 in net income (profit) each year or ($2.57) on an earnings per share basis. Cytokinetics employs 127 workers across the globe.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]


MarketBeat Community Rating for Cytokinetics (CYTK)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  372 (Vote Outperform)
Underperform Votes:  116 (Vote Underperform)
Total Votes:  488
MarketBeat's community ratings are surveys of what our community members think about Cytokinetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cytokinetics (NASDAQ:CYTK) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.892.902.903.10
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $16.78$18.20$17.90$22.00
Price Target Upside: 116.49% upside106.82% upside116.97% upside62.96% upside

Cytokinetics (NASDAQ:CYTK) Consensus Price Target History

Price Target History for Cytokinetics (NASDAQ:CYTK)

Cytokinetics (NASDAQ:CYTK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/21/2018Morgan StanleyBoost Price TargetOverweight -> Overweight$17.00 -> $18.00HighView Rating Details
2/20/2018CowenReiterated RatingBuy$11.00MediumView Rating Details
2/12/2018Cantor FitzgeraldSet Price TargetHold$10.00LowView Rating Details
1/19/2018HC WainwrightSet Price TargetBuy$20.00HighView Rating Details
11/29/2017Needham & Company LLCDowngradeStrong-Buy -> Buy$22.00 -> $12.00LowView Rating Details
11/21/2017JMP SecuritiesReiterated RatingOutperform$17.00 -> $13.00N/AView Rating Details
11/21/2017Piper Jaffray CompaniesReiterated RatingOverweight$18.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$24.00N/AView Rating Details
3/23/2017Rodman & RenshawReiterated RatingBuy$25.00MediumView Rating Details
2/17/2017FBR & CoReiterated RatingOutperform$24.00N/AView Rating Details
10/28/2016Roth CapitalSet Price TargetBuy$22.00N/AView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$16.00 -> $14.00N/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Cytokinetics (NASDAQ:CYTK) Earnings History and Estimates Chart

Earnings by Quarter for Cytokinetics (NASDAQ:CYTK)

Cytokinetics (NASDAQ CYTK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/2018($0.45)N/AView Earnings Details
2/15/2018Q4 2017($0.71)($0.75)$4.83 million($0.02) millionViewListenView Earnings Details
10/26/2017Q3 2017($0.64)($0.60)$5.35 million$6.18 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.57)($0.60)$5.28 million$3.05 millionViewListenView Earnings Details
4/27/2017Q1 2017($0.11)($0.62)$5.08 million$4.15 millionViewN/AView Earnings Details
2/16/2017Q416($0.39)$0.16$14.10 million$33.14 millionViewListenView Earnings Details
10/27/2016Q3($0.27)$0.74$6.67 million$59.05 millionViewListenView Earnings Details
7/28/2016Q2($0.28)($0.29)$7.80 million$5.80 millionViewListenView Earnings Details
4/28/2016Q1($0.37)($0.31)$8.14 million$8.42 millionViewListenView Earnings Details
2/16/2016Q415($0.32)($0.24)$10.49 million$9.80 millionViewListenView Earnings Details
10/29/2015Q315($0.30)($0.23)$11.24 million$7.90 millionViewListenView Earnings Details
7/29/2015Q2($0.28)($0.27)$4.00 million$6.54 millionViewListenView Earnings Details
4/30/2015Q1($0.08)($0.23)$10.10 million$4.40 millionViewListenView Earnings Details
2/12/2015Q4($0.17)$0.23$10.80 million$21.80 millionViewListenView Earnings Details
10/30/2014Q3($0.27)($0.16)$6.50 million$9.42 millionViewListenView Earnings Details
7/30/2014Q2($0.32)($0.23)$7.01 million$7.80 millionViewListenView Earnings Details
5/6/2014Q1($0.34)($0.27)$7.69 million$8.00 millionViewListenView Earnings Details
2/6/2014Q4($0.08)$0.21$19.14 million$24.30 millionViewListenView Earnings Details
10/30/2013Q3 2013($0.09)($0.43)$15.77 million$4.47 millionViewN/AView Earnings Details
7/31/2013Q2 2013($0.55)($0.58)$4.36 million$1.01 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.54)($0.54)$0.92 million$0.82 millionViewN/AView Earnings Details
2/5/2013Q4 2012($0.60)($0.42)ViewN/AView Earnings Details
10/30/2012Q3 2012($0.60)($0.42)ViewN/AView Earnings Details
7/31/2012Q2 2012($0.72)($0.78)ViewN/AView Earnings Details
4/26/2012Q1 2012($0.84)($0.78)ViewN/AView Earnings Details
2/2/2012Q4 2011($0.78)($0.88)ViewN/AView Earnings Details
10/27/2011Q3 2011($1.14)($0.88)ViewN/AView Earnings Details
7/28/2011Q2 2011($0.66)($1.39)ViewN/AView Earnings Details
4/27/2011Q1 2011($1.14)($1.08)ViewN/AView Earnings Details
2/14/2011Q4 2010($1.32)($1.01)ViewN/AView Earnings Details
10/28/2010Q3 2010($1.26)($1.15)ViewN/AView Earnings Details
7/28/2010Q2 2010($1.20)($1.19)ViewN/AView Earnings Details
4/29/2010Q1 2010($1.20)($1.18)ViewN/AView Earnings Details
2/3/2010Q4 2009($1.32)($1.20)ViewN/AView Earnings Details
10/28/2009Q3 2009($1.32)($0.82)ViewN/AView Earnings Details
7/29/2009Q2 2009$3.06$5.90ViewN/AView Earnings Details
4/30/2009Q1 2009($1.20)($1.24)ViewN/AView Earnings Details
2/10/2009Q4 2008($2.28)($1.31)ViewN/AView Earnings Details
10/30/2008Q3 2008($2.16)($1.67)ViewN/AView Earnings Details
7/31/2008Q2 2008($2.04)($1.87)ViewN/AView Earnings Details
4/29/2008Q1 2008($1.92)($1.69)ViewN/AView Earnings Details
1/31/2008Q4 2007($2.52)($1.61)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Cytokinetics (NASDAQ:CYTK) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.93 EPS
Next Year EPS Consensus Estimate: $-1.62 EPS

Dividends

Dividend History for Cytokinetics (NASDAQ:CYTK)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Cytokinetics (NASDAQ CYTK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.20%
Institutional Ownership Percentage: 63.67%
Insider Trades by Quarter for Cytokinetics (NASDAQ:CYTK)
Institutional Ownership by Quarter for Cytokinetics (NASDAQ:CYTK)

Cytokinetics (NASDAQ CYTK) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/16/2018Caryn Gordon McdowellInsiderSell2,709$9.00$24,381.0015,077View SEC Filing  
11/2/2017Caryn Gordon McdowellInsiderSell4,260$12.94$55,124.4017,982View SEC Filing  
11/1/2017Fady Ibraham MalikEVPSell7,321$13.39$98,028.1947,540View SEC Filing  
11/1/2017Robert I BlumCEOSell5,000$13.51$67,550.0070,180View SEC Filing  
10/6/2017Caryn Gordon McdowellInsiderSell13,181$15.49$204,173.69View SEC Filing  
10/2/2017Robert I BlumCEOSell5,000$14.59$72,950.00View SEC Filing  
9/6/2017Caryn Gordon McdowellInsiderSell10,131$14.60$147,912.6019,801View SEC Filing  
9/1/2017Robert I BlumCEOSell5,000$14.71$73,550.0079,785View SEC Filing  
8/31/2017Bradley Paul MorganSVPSell118,330$15.00$1,774,950.0063,107View SEC Filing  
8/31/2017Santo J CostaDirectorSell5,000$15.00$75,000.005,000View SEC Filing  
8/29/2017Santo J CostaDirectorSell5,000$14.00$70,000.005,000View SEC Filing  
8/8/2017Caryn Gordon McdowellInsiderSell11,348$12.47$141,509.5621,570View SEC Filing  
8/1/2017Robert I BlumCEOSell5,000$13.79$68,950.0084,785View SEC Filing  
7/3/2017Robert I BlumCEOSell5,000$12.14$60,700.0088,385View SEC Filing  
6/1/2017Robert I BlumCEOSell5,000$13.62$68,100.0094,785View SEC Filing  
12/29/2016Fady Ibraham MalikEVPSell5,633$12.36$69,623.883,361View SEC Filing  
8/31/2015L Patrick GageDirectorBuy1,000$6.95$6,950.0030,000View SEC Filing  
8/20/2015L Patrick GageDirectorBuy10,000$6.55$65,500.0030,000View SEC Filing  
5/6/2015L Patrick GageDirectorBuy10,000$5.71$57,100.00View SEC Filing  
3/11/2015Andrew A WolffCMOSell21,875$7.80$170,625.00View SEC Filing  
12/30/2014Fady Ibraham MalikSVPSell21,630$6.73$145,569.90View SEC Filing  
5/9/2014L Patrick GageDirectorBuy10,850$4.09$44,376.5010,000View SEC Filing  
2/25/2014Eastern Capital Ltdmajor shareholderBuy500,000$8.00$4,000,000.002,883,845View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cytokinetics (NASDAQ CYTK) News Headlines

Source:
DateHeadline
Cytokinetics (CYTK) PT Raised to $18.00Cytokinetics (CYTK) PT Raised to $18.00
www.americanbankingnews.com - February 21 at 5:30 PM
Cytokinetics, Inc. (CYTK) Given Average Rating of "Buy" by BrokeragesCytokinetics, Inc. (CYTK) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 21 at 2:31 PM
Cytokinetics (CYTK) Earns Buy Rating from CowenCytokinetics (CYTK) Earns Buy Rating from Cowen
www.americanbankingnews.com - February 20 at 8:26 PM
Cytokinetics Sees Unusually Large Options Volume (CYTK)Cytokinetics Sees Unusually Large Options Volume (CYTK)
www.americanbankingnews.com - February 20 at 6:56 AM
Cytokinetics (CYTK) Announces  Earnings Results, Misses Estimates By $0.04 EPSCytokinetics (CYTK) Announces Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - February 16 at 11:40 AM
Cytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results - GlobeNewswire (press release)Cytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - February 16 at 5:10 AM
Cytokinetics reports 4Q lossCytokinetics reports 4Q loss
finance.yahoo.com - February 16 at 5:10 AM
Cytokinetics, Inc. Reports Fourth Quarter 2017 Financial ResultsCytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results
finance.yahoo.com - February 16 at 5:10 AM
Cytokinetics, Inc. (CYTK) Expected to Post Quarterly Sales of $4.83 MillionCytokinetics, Inc. (CYTK) Expected to Post Quarterly Sales of $4.83 Million
www.americanbankingnews.com - February 16 at 3:46 AM
Cytokinetics Earnings Outlook - BenzingaCytokinetics Earnings Outlook - Benzinga
www.benzinga.com - February 15 at 3:10 PM
Cytokinetics to Present at the RBC Capital Markets Global Healthcare Conference - GlobeNewswire (press release)Cytokinetics to Present at the RBC Capital Markets Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - February 15 at 5:10 AM
Cytokinetics to Present at the RBC Capital Markets Global Healthcare ConferenceCytokinetics to Present at the RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - February 15 at 5:10 AM
 Analysts Expect Cytokinetics, Inc. (CYTK) Will Announce Earnings of -$0.71 Per Share Analysts Expect Cytokinetics, Inc. (CYTK) Will Announce Earnings of -$0.71 Per Share
www.americanbankingnews.com - February 14 at 5:16 PM
Cytokinetics Names Robert Califf, M.D., to Board of Directors ... - GlobeNewswire (press release)Cytokinetics Names Robert Califf, M.D., to Board of Directors ... - GlobeNewswire (press release)
www.globenewswire.com - February 14 at 3:09 PM
Cytokinetics (CYTK) Names Robert Califf to Board of DirectorsCytokinetics (CYTK) Names Robert Califf to Board of Directors
www.streetinsider.com - February 13 at 3:07 PM
Cytokinetics (CYTK) Hold Rating Reiterated at Cantor FitzgeraldCytokinetics' (CYTK) Hold Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - February 12 at 4:18 PM
Cytokinetics (CYTK) Names Robert Califf to Board of Directors - StreetInsider.comCytokinetics (CYTK) Names Robert Califf to Board of Directors - StreetInsider.com
www.streetinsider.com - February 12 at 3:07 PM
Cytokinetics: Multiple Catalysts Could Help With Rebound - Seeking AlphaCytokinetics: Multiple Catalysts Could Help With Rebound - Seeking Alpha
seekingalpha.com - February 7 at 5:15 AM
Cytokinetics (CYTK) Set to Announce Quarterly Earnings on WednesdayCytokinetics (CYTK) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 7 at 2:14 AM
Head to Head Survey: Loxo Oncology (LOXO) & Cytokinetics (CYTK)Head to Head Survey: Loxo Oncology (LOXO) & Cytokinetics (CYTK)
www.americanbankingnews.com - February 5 at 11:14 PM
Cytokinetics to Announce Fourth Quarter Results on February 15 ... - GlobeNewswire (press release)Cytokinetics to Announce Fourth Quarter Results on February 15 ... - GlobeNewswire (press release)
globenewswire.com - February 3 at 3:06 PM
Cytokinetics to Announce Fourth Quarter Results on February 15, 2018Cytokinetics to Announce Fourth Quarter Results on February 15, 2018
finance.yahoo.com - February 3 at 5:05 AM
Zacks: Brokerages Expect Cytokinetics, Inc. (CYTK) Will Announce Earnings of -$0.71 Per ShareZacks: Brokerages Expect Cytokinetics, Inc. (CYTK) Will Announce Earnings of -$0.71 Per Share
www.americanbankingnews.com - January 28 at 5:12 PM
Cytokinetics, Inc. (CYTK) Receives Consensus Recommendation of "Buy" from AnalystsCytokinetics, Inc. (CYTK) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 27 at 2:00 PM
Cytokinetics (CYTK) Given a $20.00 Price Target by HC Wainwright AnalystsCytokinetics (CYTK) Given a $20.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - January 20 at 7:38 PM
Cytokinetics (CYTK) PT Raised to $20 at HC Wainwright; The Year of CK-107 - StreetInsider.comCytokinetics (CYTK) PT Raised to $20 at HC Wainwright; 'The Year of CK-107' - StreetInsider.com
www.streetinsider.com - January 20 at 3:16 PM
Cytokinetics, Inc. (CYTK) Insider Caryn Gordon Mcdowell Sells 2,709 SharesCytokinetics, Inc. (CYTK) Insider Caryn Gordon Mcdowell Sells 2,709 Shares
www.americanbankingnews.com - January 18 at 9:58 PM
Cantor Fitzgerald Reaffirms "Hold" Rating for Cytokinetics (CYTK)Cantor Fitzgerald Reaffirms "Hold" Rating for Cytokinetics (CYTK)
www.americanbankingnews.com - January 18 at 1:50 PM
Zacks: Brokerages Anticipate Cytokinetics, Inc. (CYTK) Will Post Quarterly Sales of $4.83 MillionZacks: Brokerages Anticipate Cytokinetics, Inc. (CYTK) Will Post Quarterly Sales of $4.83 Million
www.americanbankingnews.com - January 13 at 5:00 AM
Zacks: Brokerages Anticipate Cytokinetics, Inc. (CYTK) to Announce -$0.71 EPSZacks: Brokerages Anticipate Cytokinetics, Inc. (CYTK) to Announce -$0.71 EPS
www.americanbankingnews.com - January 11 at 7:32 PM
BRIEF-Cytokinetics Announces Progress Against Vision 2020BRIEF-Cytokinetics Announces Progress Against Vision 2020
www.reuters.com - January 3 at 8:50 AM
Cytokinetics Announces Progress Against Vision 2020Cytokinetics Announces Progress Against Vision 2020
finance.yahoo.com - January 3 at 8:50 AM
$4.83 Million in Sales Expected for Cytokinetics, Inc. (CYTK) This Quarter$4.83 Million in Sales Expected for Cytokinetics, Inc. (CYTK) This Quarter
www.americanbankingnews.com - December 28 at 8:32 PM
Cytokinetics, Inc. (CYTK) Expected to Post Earnings of -$0.71 Per ShareCytokinetics, Inc. (CYTK) Expected to Post Earnings of -$0.71 Per Share
www.americanbankingnews.com - December 26 at 7:20 AM
Contrasting Cytokinetics (CYTK) and Its PeersContrasting Cytokinetics (CYTK) and Its Peers
www.americanbankingnews.com - December 12 at 7:34 PM
Cytokinetics further discusses tirasemtiv results; down 2.5% - Seeking AlphaCytokinetics further discusses tirasemtiv results; down 2.5% - Seeking Alpha
seekingalpha.com - December 12 at 5:36 PM
5 Stocks To Watch For December 11, 2017 - Benzinga5 Stocks To Watch For December 11, 2017 - Benzinga
www.benzinga.com - December 11 at 5:22 PM
Cytokinetics (CYTK) & The Competition Financial SurveyCytokinetics (CYTK) & The Competition Financial Survey
www.americanbankingnews.com - December 8 at 5:14 PM
Cytokinetics Announces Presentation of Results From VITALITY-ALS at 28th International Symposium on ALS/MNDCytokinetics Announces Presentation of Results From VITALITY-ALS at 28th International Symposium on ALS/MND
finance.yahoo.com - December 8 at 5:04 PM
Cytokinetics, Inc. (CYTK) Receives Average Rating of "Buy" from BrokeragesCytokinetics, Inc. (CYTK) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 8 at 3:52 PM
-$0.71 Earnings Per Share Expected for Cytokinetics, Inc. (CYTK) This Quarter-$0.71 Earnings Per Share Expected for Cytokinetics, Inc. (CYTK) This Quarter
www.americanbankingnews.com - December 8 at 3:30 PM
Contrasting Cytokinetics (CYTK) & The CompetitionContrasting Cytokinetics (CYTK) & The Competition
www.americanbankingnews.com - December 7 at 9:24 AM
Cytokinetics (CYTK) Says New Publication Shows Respiratory Decline Correlated With Disease Progression in People ... - StreetInsider.comCytokinetics (CYTK) Says New Publication Shows Respiratory Decline Correlated With Disease Progression in People ... - StreetInsider.com
www.streetinsider.com - December 1 at 5:01 PM
Cytokinetics Announces Results of VITALITY-ALS to be Presented at the International Symposium on ALS/MNDCytokinetics Announces Results of VITALITY-ALS to be Presented at the International Symposium on ALS/MND
finance.yahoo.com - December 1 at 5:01 PM
New Publication Summarizes Phase 1 Studies of CK-2127107 Showing Tolerability and Amplification of Skeletal Muscle Response to Nerve ActivationNew Publication Summarizes Phase 1 Studies of CK-2127107 Showing Tolerability and Amplification of Skeletal Muscle Response to Nerve Activation
finance.yahoo.com - November 30 at 5:07 PM
Cytokinetics (CYTK) Announces New Publication Summarizes Phase 1 Studies of CK-2127107 Showing Tolerability ... - StreetInsider.comCytokinetics (CYTK) Announces New Publication Summarizes Phase 1 Studies of CK-2127107 Showing Tolerability ... - StreetInsider.com
www.streetinsider.com - November 30 at 10:09 AM
Needham & Company LLC Downgrades Cytokinetics (CYTK) to BuyNeedham & Company LLC Downgrades Cytokinetics (CYTK) to Buy
www.americanbankingnews.com - November 29 at 8:44 AM
ETFs with exposure to Cytokinetics, Inc. : November 27, 2017ETFs with exposure to Cytokinetics, Inc. : November 27, 2017
finance.yahoo.com - November 27 at 6:06 PM
Cytokinetics, Incorporated (CYTK) Downgraded by Cantor Fitzgerald to "Neutral"Cytokinetics, Incorporated (CYTK) Downgraded by Cantor Fitzgerald to "Neutral"
www.americanbankingnews.com - November 22 at 12:56 PM
Reviewing Cytokinetics, (CYTK) and AveXis (AVXS)Reviewing Cytokinetics, (CYTK) and AveXis (AVXS)
www.americanbankingnews.com - November 22 at 11:30 AM

SEC Filings

Cytokinetics (NASDAQ:CYTK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cytokinetics (NASDAQ:CYTK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cytokinetics (NASDAQ CYTK) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.